Harry Moultrie

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2261218/publications.pdf

Version: 2024-02-01

62 papers	4,616 citations	159585 30 h-index	123424 61 g-index
66 all docs	66 docs citations	66 times ranked	5514 citing authors

#	Article	IF	Citations
1	Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet, The, 2022, 399, 437-446.	13.7	818
2	Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science, 2022, 376, eabn4947.	12.6	651
3	Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. New England Journal of Medicine, 2022, 386, 494-496.	27.0	570
4	Nevirapine versus Ritonavir-Boosted Lopinavir for HIV-Infected Children. New England Journal of Medicine, 2012, 366, 2380-2389.	27.0	172
5	The Contribution of Maternal HIV Seroconversion During Late Pregnancy and Breastfeeding to Mother-to-Child Transmission of HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 417-425.	2.1	129
6	Rates and Predictors of Failure of First-line Antiretroviral Therapy and Switch to Second-line ART in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 428-437.	2.1	119
7	Virologic Failure and Second-Line Antiretroviral Therapy in Children in South Africaâ€"The IeDEA Southern Africa Collaboration. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 270-278.	2.1	112
8	The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. Lancet Respiratory Medicine,the, 2022, 10, 603-622.	10.7	99
9	Challenges to Pediatric HIV Care and Treatment in South Africa. Journal of Infectious Diseases, 2007, 196, S474-S481.	4.0	94
10	Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration. South African Medical Journal, 2009, 99, 730-7.	0.6	93
11	Early Mortality and Loss to Follow-up in HIV-Infected Children Starting Antiretroviral Therapy in Southern Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 524-532.	2.1	88
12	Mortality in the Year Following Antiretroviral Therapy Initiation in HIV-Infected Adults and Children in Uganda and Zimbabwe. Clinical Infectious Diseases, 2012, 55, 1707-1718.	5.8	68
13	Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa. New England Journal of Medicine, 2022, 386, 2243-2245.	27.0	65
14	Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Lancet Infectious Diseases, The, 2022, 22, 496-506.	9.1	53
15	Changing the South African national antiretroviral therapy guidelines: The role of cost modelling. PLoS ONE, 2017, 12, e0186557.	2.5	52
16	Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. Lancet, The, 2022, 399, 1141-1153.	13.7	51
17	Antiretroviral Therapy Responses Among Children Attending a Large Public Clinic in Soweto, South Africa. Pediatric Infectious Disease Journal, 2011, 30, 974-979.	2.0	50
18	Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype. Aids, 2013, 27, 1933-1940.	2.2	48

#	Article	IF	Citations
19	Variability of Growth in Children Starting Antiretroviral Treatment in Southern Africa. Pediatrics, 2012, 130, e966-e977.	2.1	46
20	The Effect of Early Initiation of Antiretroviral Treatment in Infants on Pediatric AIDS Mortality in South Africa. Pediatric Infectious Disease Journal, 2012, 31, 474-480.	2.0	46
21	Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007: the IeDEA Southern Africa collaboration. South African Medical Journal, 2009, 99, 653-60.	0.6	44
22	Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir. Journal of Antimicrobial Chemotherapy, 2015, 70, 543-549.	3.0	42
23	Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment. Aids, 2010, 24, 1341-1349.	2.2	41
24	A survey of paediatric HIV programmatic and clinical management practices in Asia and subâ€Saharan Africaâ€"the International epidemiologic Databases to Evaluate AIDS (IeDEA). Journal of the International AIDS Society, 2013, 16, 17998.	3.0	37
25	Predictors of loss to follow-up among children in the first and second years of antiretroviral treatment in Johannesburg, South Africa. Global Health Action, 2013, 6, 19248.	1.9	36
26	Temporal Trends in the Characteristics of Children at Antiretroviral Therapy Initiation in Southern Africa: The IeDEA-SA Collaboration. PLoS ONE, 2013, 8, e81037.	2.5	36
27	Antiretroviral Therapy Outcomes in HIV-Infected Children after Adjusting Protease Inhibitor Dosing during Tuberculosis Treatment. PLoS ONE, 2011, 6, e17273.	2.5	35
28	Shortâ€term risk of anaemia following initiation of combination antiretroviral treatment in HIVâ€infected patients in countries in subâ€Saharan Africa, Asiaâ€Pacific, and central and South America. Journal of the International AIDS Society, 2012, 15, 5-5.	3.0	34
29	Six-month gain in weight, height, and CD4 predict subsequent antiretroviral treatment responses in HIV-infected South African children. Aids, 2010, 24, 139-146.	2.2	33
30	Alcohol use and sexual risk behaviour among men and women in inner-city Johannesburg, South Africa. BMC Public Health, 2017, 17, 548.	2.9	33
31	When to Start Antiretroviral Therapy in Children Aged 2â€"5 Years: A Collaborative Causal Modelling Analysis of Cohort Studies from Southern Africa. PLoS Medicine, 2013, 10, e1001555.	8.4	32
32	Virologic Response in Children Treated With Abacavir-compared With Stavudine-based Antiretroviral Treatment. Pediatric Infectious Disease Journal, 2014, 33, 617-622.	2.0	29
33	Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa. Open Forum Infectious Diseases, 2021, 8, ofab040.	0.9	27
34	Tuberculosis Immune Reconstitution Inflammatory Syndrome in Children Initiating Antiretroviral Therapy for HIV Infection. Pediatric Infectious Disease Journal, 2014, 33, 499-503.	2.0	25
35	Potent and Sustained Antiviral Response of Raltegravir-based Highly Active Antiretroviral Therapy in HIV Type 1-infected Children and Adolescents. Pediatric Infectious Disease Journal, 2012, 31, 273-277.	2.0	24
36	Prognosis of Children With HIV-1 Infection Starting Antiretroviral Therapy in Southern Africa. Pediatric Infectious Disease Journal, 2014, 33, 608-616.	2.0	24

#	Article	IF	Citations
37	A biregional survey and review of firstâ€line treatment failure and secondâ€line paediatric antiretroviral access and use in Asia and southern Africa. Journal of the International AIDS Society, 2011, 14, 7-7.	3.0	23
38	Cost and outcomes of paediatric antiretroviral treatment in South Africa. Aids, 2013, 27, 243-250.	2.2	23
39	Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa. Aids, 2013, 27, 781-785.	2.2	22
40	Accuracy of immunological criteria for identifying virological failure in children on antiretroviral therapy â€“ The IeDEA Southern Africa Collaboration. Tropical Medicine and International Health, 2011, 16, 1367-1371.	2.3	21
41	Immune Recovery After Starting ART in HIV-Infected Patients Presenting and Not Presenting With Tuberculosis in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 142-145.	2.1	21
42	Tuberculosis and the risk of opportunistic infections and cancers in <scp>HIV</scp>â€infected patients starting <scp>ART</scp> in Southern Africa. Tropical Medicine and International Health, 2013, 18, 194-198.	2.3	20
43	Virologic Failure Among Children Taking Lopinavir/Ritonavir-containing First-line Antiretroviral Therapy in South Africa. Pediatric Infectious Disease Journal, 2015, 34, 175-179.	2.0	20
44	Correlation of rpoB Mutations with Minimal Inhibitory Concentration of Rifampin and Rifabutin in Mycobacterium tuberculosis in an HIV/AIDS Endemic Setting, South Africa. Frontiers in Microbiology, 2016, 7, 1947.	3.5	20
45	Paradoxical tuberculosisâ€associated immune reconstitution inflammatory syndrome in children. Pediatric Pulmonology, 2016, 51, 157-164.	2.0	17
46	Predictors of Virologic and Clinical Response to Nevirapine versus Lopinavir/Ritonavir-based Antiretroviral Therapy in Young Children With and Without Prior Nevirapine Exposure for the Prevention of Mother-to-child HIV Transmission. Pediatric Infectious Disease Journal, 2014, 33, 846-854.	2.0	16
47	Viral load versus CD4+ monitoring and 5-year outcomes of antiretroviral therapy in HIV-positive children in Southern Africa. Aids, 2014, 28, 2451-2460.	2.2	12
48	Focus on adolescents with HIV and AIDS. South African Medical Journal, 2014, 104, 897.	0.6	11
49	Effect of Baseline Immune Suppression on Growth Recovery in HIV Positive South African Children Receiving Antiretroviral Treatment. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 235-242.	2.1	10
50	Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial. PLoS Medicine, 2022, 19, e1004024.	8.4	10
51	The role of targeted viral load testing in diagnosing virological failure in children on antiretroviral therapy with immunological failure. Tropical Medicine and International Health, 2012, 17, 1386-1390.	2.3	9
52	Evaluation of the intensified tuberculosis case finding guidelines for children living with HIV. International Journal of Tuberculosis and Lung Disease, 2018, 22, 1322-1328.	1.2	9
53	The Effect of Tuberculosis Treatment on Virologic and Immunologic Response to Combination Antiretroviral Therapy Among South African Children. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 136-144.	2.1	5
54	Microbiological investigation for tuberculosis among HIV-infected children in Soweto, South Africa. International Journal of Tuberculosis and Lung Disease, 2014, 18, 676-681.	1.2	5

#	Article	IF	Citations
55	A position statement and practical guide to the use of particulate filtering facepiece respirators (N95,) Tj ETQq1 1 0.784314 rgBT /Ov Mycobacterium tuberculosis and SARS-CoV-2. African Journal of Thoracic and Critical Care Medicine, 2021, 26, .	0.6	5
56	A geospatial analysis of two-hour surgical access to district hospitals in South Africa. BMC Health Services Research, 2020, 20, 744.	2.2	4
57	Growth in Virologically Suppressed HIV-Positive Children on Antiretroviral Therapy. Pediatric Infectious Disease Journal, 2015, 34, e254-e259.	2.0	3
58	CHAPAS-3 fills the gap. Lancet Infectious Diseases, The, 2016, 16, 133-134.	9.1	2
59	Outcomes in treatment with darunavir/ritonavir in ART-experienced paediatric patients. South African Medical Journal, 2015, 105, 330.	0.6	2
60	Protective Effect of HIVâ€Positive Primary Caregivers on Mortality in Children Receiving Antiretroviral Therapy?. Journal of Infectious Diseases, 2008, 198, 939-940.	4.0	1
61	Novel biomarkers for paediatric tuberculosis. Lancet Infectious Diseases, The, 2014, 14, 900-901.	9.1	1
62	Advancing TB research using digitized programmatic data. International Journal of Tuberculosis and Lung Disease, 2021, 25, 890-895.	1.2	1